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Introduction
Adalimumab (ADA) is approved for use in moderate to
severe juvenile idiopathic arthritis (JIA) in patients (pts)
≥4 years (yrs) old in the US, EU, and Japan. Limited
data are available in pts <4 yrs old.
Objectives
To assess the safety and effectiveness of >1 year of ADA
therapy in pts aged 2 to <4 yrs old or ≥4 yrs old weighing
<15 kg with moderately to severely active polyarticular JIA
Methods
JIA pts were treated with ADA 24 mg/m2 (maximum =
20 mg/dose) every other week (wk) +/- methotrexate
for a minimum of 24 wks in an ongoing international,
multicenter, open-label, phase 3b study until achieving
the limit for age (≥4 yrs) and weight (≥15 kg). Adverse
events (aes) were summarized for all visits up to 96 wks.
Clinical effectiveness endpoints were assessed as
observed, and included American College of Rheumatology
pediatric (pedacr) 30/50/70/90 responses through wk 60,
and JIA outcome parameters (Physician’s Global Assess-
ment [phga] and Parent Global Assessment [paga] of Dis-
ease Activity, paga of Pain [all 3 on a VAS of 0-100 mm],
Disability Index of Childhood Health Assessment Ques-
tionnaire [DICHAQ], Active Joint Count [AJC73], Limita-
tion on Passive Motion [LOM69], C-Reactive Protein
[CRP], Tender Joint count [TJC], Swollen Joint Count
[SJC], and Pain on Passive Motion [POM75]).
Results
32 pts were randomized; through wk 60, two pts with-
drew due to aes (JIA worsening or flare) and 2 withdrew
for other reasons. AE incidence rates included: any aes
(91%), serious aes (16%), infectious aes (78%), and serious
infections (9%). No deaths, malignancies, or opportunis-
tic infections were reported. 90% of pts had achieved
pedacr30 at wk 60 (Table 1). High pedacr 50/70/90
response rates were achieved at wk 24 and maintained
through wk 60. Statistically significant improvements in
other JIA outcomes were also observed at wk 60. Mean
change (SD) for these outcomes were: phga [-42.7(28.2)],
paga [-34.5 (33.3)], DICHAQ [-0.6 (0.7)], AJC73
[-9.5 (7.5)], LOM69 [-5.5 (8.3)], CRP(mg/dl) [-0.3 (1.8)],
TJC75 [-4.5 (5.9)], SJC66 [-8.4 (7.2)], POM75 [-5.9 (5.3)],
and paga of Pain [-35.2 (34.4)]. Growth was not adversely
impacted by ADA treatment; based on CDC growth
standards, at baseline, 50%/53% of pts were in the ≥33rd
percentile for height and body mass index, respectively;
at wk 60, this had increased to 76%/67%.
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Table 1 Pedacr Response Over Time
Week 24 Response Rate
N = 30
N (%)
Week 60 Response Rate
N = 20
N (%)
Pedacr 30 27 (90.0) 18 (90.0)
Pedacr 50 25 (83.3) 16 (80.0)
Pedacr 70 22 (73.3) 14 (70.0)
Pedacr 90 11 (36.7) 10 (50.0)
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Conclusion
In this very young population with polyarticular JIA, pri-
mary clinical trial data revealed that the safety profile
and effectiveness of ADA were comparable to that
observed in older children with JIA. Moreover, ADA
had no adverse impact on height or weight, as data
reflected improvement in growth metrics through wk 60
of the study.
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